Antimicrobial resistance leads to more than one million deaths a year. One in four cancer patients is battling a serious infection – if the cancer medication works, an untreatable infection can still kill them.
Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.
With collective determination, an open mindset and willingness to do things differently, Europe can set an example in the fight against antimicrobial resistance. Huw Tippett, CEO of Shionogi Europe, calls for collective action ahead of the European Hea…
